Chiral therapeutics already makes up over one-third of pharmaceutical drugs currently sold worldwide. This is a growing industry with global chiral drug sales for 2002 increasing by 12%to $160 billion (Technology Catalysts International) of a total drug market of $410bn. The increasing demand to produce enantiomerically pure pharmaceuticals, agrochemicals, flavors, and other fine chemicals has advanced the field of asymmetric catalytic technologies.We aim to become a high value technology provider and partner in the chiral therapeutics industry by offering proprietary catalysts, novel building blocks, and collaborative synthetic solutions. In decade, we have developed a set of novel chiral homogeneous phosphorus ligands such as Binaphane, Me-KetalPhos, TangPhos, f-Binaphane, Me-f-KetalPhos, C4TunePhos and Binapine,which we called Chiral Ligand ToolKit. Complementing the ToolKit, (R, S, S, R)-DIOP*, T-Phos,o-BIPHEP, o-BINAPO and FAP were added recently[1].These ligands can be applied to a broad variety of drug structural features by asymmetric hydrogenation of dehydroamino acid derivatives, enamides, unsatisfied acids and esters, ketones,beta ketoesters, imines and cyclic imines. And ligand FAP had been apllied succefully in allylic alkylation and [3+2] cycloaddition.